“Even in patients that have only been single-stone formers, especially those that have required surgical stone removal, we believe that medical prevention is warranted to prevent recurrent stones,” says Glenn M. Preminger, MD.
In this video, Glenn M. Preminger, MD, assesses the challenges and methods involved in stone prevention. Preminger is presenting the John K. Lattimer Lecture, "Kidney stones: Is prevention possible?" at the 2021 American Urological Association annual meeting. Preminger is a urologist and professor of surgery at Duke University Medical Center, Durham, North Carolina.
KIM-1 emerges as biomarker for MRD, atezolizumab benefit in renal cell carcinoma
June 3rd 2024Circulating kidney injury molecule-1 (KIM-1) may be a biomarker for minimal residual disease, disease recurrence, and benefit from adjuvant atezolizumab in patients with renal cell carcinoma at increased risk of recurrence, according to a retrospective analysis of the phase 3 IMmotion010 trial.